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dren that received at least 1 homeopathic drug and no
antibiotics, and strategy A 190 children that received at
least 1 antibiotic and no homeopathic drugs. In both
strategies, other drugs could have been prescribed.
Medical effectiveness was assessed by measuring the
number of bouts of acute rhinopharyngitis, the number
of complications, and the quality of family life using the
Par-Ent-Qol© scale. Direct medical costs (medical visits,
medication, additional tests) and indirect costs (sick-
leaves) were assessed from the national health insurance
system viewpoint, using public prices and French Social
Security tariffs. We checked the comparability of patient
population and performed appropriate statistical tests:
Chi-Square test for qualitative variables, and Student,
Mann-Whitney, Kolmogorov-Smirnov tests for quantita-
tive variables. RESULTS: The “homeopathic drugs”
strategy produced signiﬁcantly better results in terms of
medical effectiveness (number of bouts: 2.71 vs 3.97,
number of complications: 1.25 vs 1.95) and quality of life
(global score: 21.38 vs 30.43), for signiﬁcantly lower
direct medical costs reimbursed by the national health
insurance system (88€ vs 99€) and fewer number of sick-
leaves (23 vs 60). CONCLUSION: Homeopathic drugs
could constitute a cost-effective alternative to antibiotics
for treating rhinopharyngitis, and so could provide an
answer to public health and economic problems posed by
the inappropriate use of these drugs in this disease in
France.
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OBJECTIVES: The objective of this study was to inves-
tigate the effect of capitation on the inpatient and out-
patient expenditures by private health plans for asthma
treatment. METHODS: Data were drawn from the
MEDSTAT Group’s MarketScan database, which has
health care claims data from large employment-based
health insurers. The sample includes 106,943 patients
enrolled in 1999 in one of 5 different types of health
plans: a Health Maintenance Organization (HMO), a
capitated Point-of-Service plan (CPOS), a non-capitated
Point-of-Service plan (NCPOS), a Preferred Provider
Organization (PPO), and a traditional comprehensive
indemnity plan (COMP). The ﬁrst two plans are capi-
tated, and the last three are non-capitated, or fee-for-
service plans. We compared the mean payment between
capitated and non-capitated systems for outpatient and
inpatient care by using t-test for a mean. RESULTS: Cap-
itated plans had signiﬁcantly smaller payments per visit
for outpatient claims ($56 for CPOS and $59 for HMO)
relative to non-capitated COMP ($67), PPO ($71) and
NCPOS ($72) plans (p-value < 0.01). Similarly, mean
payment for each hospitalization under HMO ($3748)
and CPOS ($3783) plans was also signiﬁcantly lower
than under NCPOS ($4139), COMP ($4746), and PPO
($4890) plans (p-value < 0.01). This trend held for all
subgroups, with hospitalization for women being more
costly than for men, $4244 versus $3397 in average for
capitated (p-value < 0.01) and $5090 versus $4204 in
average for non-capitated plans (p-value < 0.01), and for
all age cohorts. CONCLUSION: The mean payment for
outpatient visits and for hospitalizations for asthma
patients in capitated health plans were signiﬁcantly lower
than for non-capitated plans, and these savings in
payment were especially apparent for the case of out-
patient care. Further studies are necessary to determine 
if these “savings” are consistent with quality asthma 
outcomes.
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OBJECTIVES: Audience participants will: 1) understand
the beneﬁts associated with a health plan establishing a
contract with a specialty distributor for the cost-effective
procurement of an expensive injectable; 2) evaluate the
challenges to establishing a contract with a specialty
provider and investigate the steps necessary to foster a
smooth transition for the health plan; and 3) learn about
palivizumab and its prudent use in infants who are at risk
for Respiratory Syncytial Virus (RSV). METHODS:
Due to the high cost of palivizumab, pediatricians were
obtaining referrals for babies to receive monthly
palivizumab injections through an outpatient hospital
setting. The health plans’ cost for hospital administration
was $5225 per palivizumab injection. As a result, the
health plan established a contract with a specialty
injectable provider that supplied the drug at a discount
off average wholesale price (AWP). The drug was then
sent by the specialty distributor to either the physicians’
ofﬁce or the parents’ home for administration. RESULTS:
Through this initiative a cost savings of $3675 per injec-
tion resulted. A total of ﬁfteen at risk infants received
injections during the months of November through April
2001, none of which required hospitalization during 
the Respiratory Syncytial Virus (RSV) season. The health
plan experienced a total cost avoidance of over $180,000
and had the potential to save over $300,000 if all 15
infants were identiﬁed at the beginning of RSV season
(October). CONCLUSION: Establishing a contract with
a specialty distributor can prove to be cost effective for
health plans with large member populations. It is advan-
tageous for the health plan to pursue specialty providers
for the procurement of specialty injectables like
palivizumab, and at the same time provide quality patient
care.
